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doi:10.101Rapid Transport and Infusion of Hematopoietic
Cells Is Associated with Improved Outcome after
Myeloablative Therapy and Unrelated Donor
Transplant
Hillard M. Lazarus,1 Fangyu Kan,2 Sergey Tarima,3 Richard E. Champlin,4 Dennis L. Confer,2
Noelle Frey,5 Adrian P. Gee,6 John E. Wagner,7 Mary M. Horowitz,3 Mary Eapen3We evaluated effects of graft transport time on outcomes after transplantation of 938 unrelated donor bone
marrow (BM) or 507 peripheral blood progenitor cells (PBPC) in patients with acute or chronic leukemia and
myelodysplastic syndrome (MDS). BM grafts were collected at 107 centers and PBPC, 89 centers. Median
time from end of collection to infusion was 14 hours for BM and 15 hours for PBPC. Platelet recovery
was less likely in BM recipients when the interval from end of collection to receipt at transplant center
was $20 hours (odds ratio 0.47, P 5 .010) and when the interval from receipt to infusion was $6 hours
(odds ratio 0.57, P5 .001). Mortality rates were higher in recipients of HLA-matched BM when the interval
from end of collection to receipt at transplant center was $20 hours (relative risk 2.67, P\.001) after ad-
justment for other significant prognostic factors. Mortality after HLA-mismatched BM transplants was not
associated with transport time. Transport times had no demonstrable effect on outcomes after PBPC trans-
plants. These data support a general review of current transport procedures, especially for BM grafts requir-
ing longer transport time and every effort made to minimize time from collection to infusion.
Biol Blood Marrow Transplant 15: 589-596 (2009)  2009 American Society for Blood and Marrow TransplantationKEY WORDS: Transport of unrelated donor grafts, Transport times, Transplant outcomesINTRODUCTION
HLA-matched sibling hematopoietic cell transplan-
tation (HCT) is the treatment of choice for a variety of
malignant and nonmalignant disorders [1]. Only about
30% of candidates, however, will have a suitable unre-
lated histocompatible or matched-related donor to pro-
vide an allogeneic graft [2]. Patients without a related
donor must identify a suitable unrelated donor through1University Hospitals Case Medical Center, Cleveland,
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6/j.bbmt.2009.01.017large international registries. Almost all unrelated donor
grafts are collected at a site remote from the site where
the recipient is treated. Significant advances, including
the discovery of new HLA alleles, the development of
precise and efficient HLA typing methods using DNA
technology, the implementation of more selective im-
munosuppressive agents to decrease treatment-related
toxicity, and graft-versus-host disease (GVHD), and
prophylaxis for viral and fungal infections, has enabled
more effective identification and use of unrelated
donors for HCT [3–5]. Registry data now indicate
that more than a third of allogeneic transplants now
use unrelated donors and outcomes have improved
progressively over the past 20 years [6].
More than 10millionHLA-typed volunteer donors
are available world wide to donate bone marrow (BM)
or peripheral blood progenitor cells (PBPC). Most of
these donors are available through the U.S. National
Marrow Donor Program (NMDP) [7]. The collection
and transport of cells for infusion is a complex process
coordinated by theNMDP for transplants it facilitates.
Grafts are collected at sites accredited by the NMDP
and are transported according to specified guidelines.
The NMDP recommendations for graft transport are
available at www.marrow.org (NMDP Standards,
19th edition, 2004). Because there may be great589
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there is the potential for long delays between collection
and infusion that could impact upon graft viability.We
studied this issue in more than 1400 transplants facili-
tated by the NMDP.PATIENTS AND METHODS
Data Collection
Data on transportation and characteristics of
PBPC and BM grafts were collected by the NMDP.
Detailed demographic, disease, and transplant charac-
teristics and outcome data were obtained on all unre-
lated donor transplant recipients facilitated by the
NMDP in the United States and participating interna-
tional centers. Patients were followed longitudinally.
Computerized error checks, physician review of sub-
mitted data, and on-site audits of participating centers
were performed to ensure data quality.
Inclusion Criteria
The study population includes 938 recipients of BM
and 507 recipients of PBPC transplants during the pe-
riod 2000 to 2004. This study was restricted to patients
receivingHCT for acute leukemia (acute lymphoblastic
leukemia [ALL] or acute myelogenous leukemia
[AML]), chronic myelogenous leukemia (CML), or
myelodysplastic syndrome (MDS).Only patients in first
or second clinical remission, chronic phase, and refrac-
tory anemia and receiving a myeloablative conditioning
regimen were included. Myeloablative conditioning
regimen was defined as total body irradiation (TBI)
dose.500 cGy (singledose) or.800 cGy (fractionated)
withother agents, andfornonirradiationregimens, abu-
sulfan (Bu) dose of at least 9mg/kg or amelphalan (Mel)
dose .150 mg/m2. Excluded were patients who re-
ceived regimens of lower intensity to that mentioned
above, second or subsequent transplantation, patients
with more advanced leukemia, other hematologic ma-
lignancies and nonmalignant diseases, T cell-depleted
BMorCD34 selected PBPC transplants, cryopreserved
BM,orPBPCgrafts. Informed consent for survivingpa-
tientswasobtained in accordancewith thedeclarationof
Helsinki. Informed consent was waived by the NMDP
institutional review board for all deceased patients. Ap-
proximately12%of survivingpatients in theNMDPda-
tabase did not provide consent for use of data for
research. To adjust for the potential bias introduced
by the exclusion of 12%of surviving patients and the in-
clusion of all deceased patients a probability model ran-
domly excluded approximately the same percentage of
deceased patients (n 5 166). This probability model
uses a biased coin randomizationmethodwith exclusion
probabilities based on the patient and disease character-
istics associated with patients who did provide consent
for research [8].Graft Transport
Bags containing BM or PBPC were placed in an
outer bag to prevent leakage. Collection bag(s) were
enclosed in a rigid container with temperature insulat-
ing properties. All products were noncryopreserved
and transported at the temperature specified by the
transplant center or the NMDP. NMDP guidelines
recommend transportation at ambient temperature
for BM and refrigeration for PBPC; transport temper-
ature (ambient or refrigerated for either graft) could
also be requested by the transplant center. No product
had direct contact with wet ice or frozen gel packs. The
temperature at which the grafts were transported was
not monitored. All products were hand carried by
a courier. TheNMDP ensures transportation arrange-
ments, for the courier minimizes transit time from
collection to transplant centers. Ninety-three percent
of BM grafts were transported at ambient temperature
and 7% refrigerated at the request of the transplant
center; 98% of PBPC grafts were transported refriger-
ated and 2% at ambient temperature.
Endpoints
The primary outcomes studied were neutrophil
and platelet recovery, acute and chronic graft-versus-
host disease (aGVHD, cGVHD), early (day 100) and
overall mortality. Neutrophil recovery was defined
as achieving an absolute neutrophil count (ANC)
$0.5  109/L; platelet recovery was defined as achiev-
ing a platelet count $20  109/L, unsupported for 7
days. Failure to achieve an ANC$0.5 109/L or a de-
cline to \0.5  109/L after an initial recovery and
without a subsequent recovery was considered graft
failure. Incidence of grades ii, iii, and iv aGVHD and
cGVHD were determined in all patients. Diagnosis
of aGVHD and cGVHD [9,10] was based on local in-
stitutional criteria, with overall grade of aGVHD as-
signed retrospectively by the NMDP based on stage
of involvement reported for each individual organ.
Early mortality was defined as death from any cause
within the first 100 days after transplantation and over-
all mortality, death from any cause at any time.
Statistical Analysis
The probabilities of early (day 100) mortality and
overall survival (OS) were calculated using the Kaplan-
Meier estimator [11]. For analysis of survival, death
fromany causewas considered an event, and data on sur-
viving patients were censored at time of last follow-up.
The probabilities of neutrophil and platelet recovery,
and aGVHDand cGVHDwere calculated using the cu-
mulative-incidence-function method [12]. For neutro-
phil and platelet recovery and GVHD, death without
an event (hematopoietic recovery or GVHD) was the
competing event. Data on patients without an event
were censored at last follow-up. Confidence intervals
Table 1. Patient, Disease, and Transplant Characteristics
Bone Marrow Peripheral Blood
Variables Number (%) Number (%)
Total number 938 507
Sex, male 539 (57) 288 (57)
Recipient age
<18 years 284 (30) 80 (16)
$18 years 654 (70) 427 (84)
Performance score
90-100 705 (75) 356 (70)
<90 139 (15) 97 (19)
Unknown 94 (10) 54 (11)
Disease
Acute myelogenous leukemia 315 (34) 220 (43)
Acute lymphoblastic leukemia 309 (33) 160 (32)
Chronic myelogenous leukemia 281 (30) 88 (17)
Myelodysplastic syndrome 33 (4) 39 (8)
Disease status
First clinical remission or chronic
phase or refractory anemia
534 (57) 312 (62)
Second clinical remission or
chronic phase
404 (43) 195 (38)
Collection center
Domestic 877 (93) 466 (92)
International 61 ( 7) 41 ( 8)
Total nucleated cell dose at end of collection
<3  108/kg 234 (25) 16 ( 3)
$ 3 x 108/kg 699 (75) 478 (94)
Unknown 5 (<1) 13 ( 3)
Time from end of collection to receipt at transplant center
<5 hours 69 ( 7) 31 ( 6)
5-9 hours 470 (50) 206 (41)
10-19 hours 345 (37) 205 (40)
$20 hours 54 ( 6) 65 (13)
Temperature of graft during shipping
Ambient 874 (93) 10 ( 2)
Refrigerated 64 ( 7) 496 (98)
Total nucleated cell dose at receipt at transplant center
<3  108/kg 291 (31) 20 (4)
$ 3 x 108/kg 641 (68) 446 (88)
Unknown 6 (<1) 41 ( 8)
Manipulation of graft prior to infusion
None 374 (40) 409 (81)
ABO incompatibility 564 (60) 97 (19)
Unknown – 1 (<1)
Time from receipt at transplant center to infusion into patient
<3 hours 421 (45) 269 (53)
3-5 hours 283 (30) 102 (20)
6-9 hours 55 ( 6) 26 ( 5)
$10 hours 179 (19) 110 (22)
Total transport time, median (range)
hours
14 (3-51) 15 (2-55)
Donor age
18-30 years 344 (37) 163 (32)
31-40 years 342 (36) 189 (37)
41-60 years 252 (27) 155 (31)
Donor-recipient cytomegalovirus serostatus
Donor (2)/recipient (2) 302 (32) 160 (32)
Donor (2)/recipient (+) 257 (27) 161 (32)
Donor (+)/recipient (2) 151 (16) 67 (13)
Donor (+) / recipient (+) 210 (22) 103 (20)
Unknown 18 ( 2) 16 ( 3)
Donor-recipient sex match
Male donor/ male recipient 351 (37) 188 (37)
Male donor/ female recipient 222 (24) 118 (23)
Female donor/ male recipient 188 (20) 100 (20)
Female donor/ female recipient 177 (19) 101 (20)
Donor-recipient ABO match
Matched 386 (41) 194 (38)
Minor mismatch 248 (26) 131 (26)
Major mismatch 227 (24) 139 (27)
(Continued )
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log-transformation.
Cox regression models were built for analyses of
risk factors for GVHD and overall mortality and logis-
tic regression models for analysis of neutrophil and
platelet recovery and day 100 mortality [12,13]. BM
and PBPC transplantations were analyzed separately.
All multivariate models were built using stepwise
forward selection, with a value ofP5 .01 or less consid-
ered to indicate statistical significance.We used a value
of P# .01 to indicate statistical significance because of
the number of variables considered in model building
(Table 1). Variables were categorized as follows: recip-
ient age ($18 vs.\18 years), performance score (90-
100 versus \90), disease (ALL versus MDS versus
CML versus AML), disease status (first complete re-
mission or chronic phase or refractory anemia versus
second clinical remission or chronic phase), total nu-
cleated cell (TNC) dose at end of collection ($3 versus
\3 108/kg), interval from end of collection to receipt
at transplant center ($20 versus\20 hours), shipping
temperature (refrigerated versus ambient), TNC cell
dose at receipt at transplant center ($3 versus\3 
108/kg), interval from receipt at transplant center to in-
fusion ($6 versus\6 hours), processing of graft for
ABO incompatibility versus none, donor-recipient
HLA disparity (matched versus mismatched), donor-
recipient cytomegalovirus (CMV) status (donor and re-
cipient negative versus donor negative/recipient posi-
tive versus donor positive/recipient negative versus
donor and recipient positive), donor-recipient sex
match (female donor/ male recipient versus other),
conditioning regimen (TBI containing regimens versus
nonirradiation regimens),GVHDprophylaxis (tacroli-
mus versus cyclosporine [CsA]), and year of transplant
(2000-2002 versus 2003-2004). As the primary out-
come of the study was to access impact of transport
times (interval from end of collection to receipt at
transplant center and from receipt at transplant center
to infusion), these variables were held in all finalmodels
regardless of statistical significance.
All variablesmet the proportional-hazards assump-
tion.Martingale residual plots were constructed for the
following variables to determine the appropriate cutoff
points for inclusion in the model as a binary variable:
interval from end of collection to receipt at transplant
center and from receipt at transplant center to infusion.
These plots were constructed for each outcome of
interest to ensure that the cutoff point was appropriate
for all of the outcomes studied. In addition, we exam-
ined the above-mentioned time periods by the cate-
gories shown in Table 1; the cutoff points determined
by both methods were comparable. Consequently, we
chose 20 hours as the cutoff point for time between
end of collection and receipt at transplant center and
6 hours, the cutoff point for time between receipt at
transplant center and infusion. Among BM recipients,
Table 1. (Continued )
Bone Marrow Peripheral Blood
Variables Number (%) Number (%)
Bidirectional 65 ( 7) 42 ( 8)
Unknown 12 ( 1) 1 (<1)
Donor-recipient HLA match*
Well matched 516 (55) 334 (66)
Partially matched 297 (32) 119 (23)
Mismatched 125 (13) 54 (11)
Conditioning regimen
Cyclophosphamide + total body
irradiation
694 (74) 333 (66)
Total body irradiation + other 19 ( 2) 29 ( 6)
Cyclophosphamide + busulfan 193 (21) 126 (25)
Busulfan + fludarabine
+antithymocyte globulin
21 ( 2) 12 ( 2)
Busulafan + cytosine arabinoside 1 (<1) –
Melphalan + fludarabine
+antithymocyte globulin
10 ( 1) 7 ( 1)
Graft-versus-host disease prophylaxis
Tacrolimus ± other 378 (40) 246 (49)
Cyclosporine ± other 560 (60) 261 (51)
Year of transplant
2000-2002 606 (65) 202 (40)
2003-2004 332 (35) 305 (60)
Follow up of surviving patients,
median (range) months
48 (6-85) 36 (3-76)
Partially matched includes: single locus antigen or allele-level multiple
myeloma (MM) at A, B, C, or DRB1 (bone marrow [BM]; n 5 238, pe-
ripheral blood progenitor cell [PBPC]; n 5 108); matched at low reso-
lution A, B, C, and DRB1(BM; n5 2, PBPC; n5 3); 1 allele mismatch at
high-resolution A, B, and DRB1 and HLA-C unknown (BM; n 5 1);
matched at low-resolution A, B, and high-resolution DRB1 and HLA-
C unknown (BM; n 5 56, PBPC; n 5 8).
Mismatched includes: >1 allele or antigenMM at A, B, C, DRB1 (BM; n5
111, PBPC; n5 48); 1 antigen MMwhen low resolution available at A, B,
C, DR (BM; n5 1, PBPC; n5 1); 1 antigen or$2 allele mismatch at high-
resolution A, B, DRB1, and HLA-C unknown (BM; n5 3); 1 mismatch at
low resolution A, B, high-resolution at DRB1 and HLA-C unknown (BM;
n5 10, PBPC; n5 3); matched at low-resolution A, B, DRB1, and HLA-
C unknown (PBPC; n 5 2).
*Well-matched includes: 8/8 allele-level matched (BM; n 5 355, PBPC;
n 5 244); allele-level matched A, B, DRB1 and low-resolution matched
at HLA-C (BM; n5 31, PBPC; n5 15); low- resolution matched at A, B,
and C and allele-level DRB1 (BM; n 5 126, PBPC; n 5 69); allele-level
matched at A, B, DRB1, and HLA-C unknown (BM; n5 4, PBPC; n5 6).
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recipientHLAmatch and interval fromendof collection
to receipt at transplant center and, type of leukemia and
disease status at transplantation for overall mortality.
We examined for a collection center and transplant
center effect on OS and found none. The P-values are
2 sided. Analyses were performed using SAS software,
version 9.1 (SAS Institute, Cary, NC).RESULTS
Patient, disease, graft transport, and transplant char-
acteristics are shown in Table 1.Donor high-resolution
HLA typing (HLA A, B, C, and DRB1) were available
for 55% of the study population, these data generatedby the NMDP’s high-resolution HLA typing project.
For the remaining 45%, HLA data as submitted by
transplant centers were used. The classification of do-
nor-recipient HLA compatibility used herein follows
publishedNMDP guidelines [14]. BM transplantations
occurred at 115 transplant centers and PBPC trans-
plantations at 80 centers.Bone Marrow Grafts
BM grafts were collected at 93 centers in the
United States and at 14 international locations. All
BM grafts involved a single collection. Sixty-one grafts
were transported from an international collection cen-
ter to a U.S. transplant center, and 49 from a U.S. col-
lection center to an international transplant center
(12% of BM grafts involved international transport).
Median time from end of collection to receipt at trans-
plant center for domestic collection was 9 hours
(range:\1-47 hours). Median time for international
transport was longer at 19 hours (range: 9-40 hours).
Sixty percent of grafts (n 5 564) were manipulated
for donor-recipient ABO incompatibility. Median
time from receipt at transplant center to infusion was
3 hours (range:\1-45). The median cell doses prior
to shipping from the collection center and receipt at
transplant center were 3.8  108/kg (range: \1.0-
35.5) and 3.6  108/kg (range:\1.0-28.6). The cell
concentration of almost all of the BM grafts (99%) at
collection and shipping was #5.0  107/mL.
Neutrophil and Platelet Recovery
Neither the interval from end of collection to
receipt at transplant center or from receipt at trans-
plant center to infusion was associated with neutrophil
recovery (Table 2A). In contrast, the probability of
platelet recovery was lower when interval from end
of collection to receipt at transplant center was $20
hours and when receipt at transplant center to infusion
was $6 hours, adjusted for other significant factors
(Table 3A). This effect was independent of cell dose
and graft manipulation for donor-recipient ABO
incompatibility. Secondary graft failure rate was 9%;
a third of graft failures were associated with recurrent
leukemia.
Overall Mortality
Four hundred thirty-one of 938 BM recipients are
alive with a 1-year probability of OS of 58% (95% con-
fidence interval [CI] 55%-62%). Early mortality (day
100) rates were not associated with interval from end
of collection to receipt at transplant center (odds ratio
[OR] 1.31, 95% CI 0.69-2.50, P 5 .413) or from
receipt at transplant center to infusion (OR 1.37,
95% CI 0.96-1.95, P 5 .087). However, overall mor-
tality was higher when the interval from end of collec-
tion to receipt at transplant center of anHLA-matched
Table 2A. Probability of Neutrophil Recovery at 28 Days
after BM Transplants
Variables N
Odds Ratio for Recovery
(95% Confidence Interval) P-Value
Time from end of collection to receipt, hours
<20 880 1.00
$20 53 0.55 (0.22-1.34) .186
Time from receipt to infusion, hours
<6 699 1.00
$6 234 0.90 (0.50-1.60) .711
Total nucleated cell dose at end of collection
< 3  108/kg 234 1.00
$3  108/kg 699 2.24 (1.32-3.78) .003
BM indicates bone marrow.
Table 2B. Probability ofNeutrophil Recovery at 28Days after
PBPC Transplants
Variables N
Odds Ratio for Recovery
(95% Confidence Interval) P-Value
Time from end of collection to receipt, hours
<20 442 1.00
$20 65 0.36 (0.13-0.95) .039
Time from receipt to infusion, hours
<6 371 1.00
$6 136 0.59 (0.24-1.46) .257
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after mismatched BM transplants were not associated
with the interval from end of collection to receipt at
transplant center. The interval from receipt at trans-
plant center to infusion was not associated with
mortality after either matched or mismatched BM
transplants.
We also examined the time from end of collection
to infusion (the sum of transport time and time from
receipt at transplant center to infusion). After adjusting
for significant factors (disease status at transplantation,
donor-recipient HLA disparity and year of transplant),
patients (n 5 813) who received BM grafts within 26
hours of collection had a significantly lower rate of
mortality compared to those (n 5 125) who received
their BM graft beyond 26 hours from end of collection
(realtive risk [RR] 0.66, 95% CI 0.52-0.84, P\ .001).
Among the grafts that traveled for\20 hours or were
infused \6 hours after receipt, we did not identify
a shorter interval that conferred a survival advantage.PBPC
Collection of PBPC occurred at 89 centers; 81 U.S.
centers and the remaining 8 at international locations.
Forty-one grafts were collected at an international col-
lection center and transported to the United States and
22 were collected in the United States and transported
to an international transplant center (12% of PBPC
grafts involved international transport). Two hundred
eleven (42%) PBPC collections involved a single collec-
tion and 296 (58%), 2 collections.When a donor had to
be collected twice, products fromdays 1 and2were ship-
ped at the end of the second collection. Median time
from end of collection to receipt at transplant center
for domestic collection was 10 hours (range: \1-32
hours). Transport time was longer with international
transport, 32 hours (range: 7-45 hours). Ninety-seven
(19%) PBPC grafts were manipulated for donor-recipi-
ent ABO incompatibility and none CD34 selected. Me-
dian time from receipt at transplant center to infusion
was 3hours (range:\1-39hours).Themedian cell doses
prior to shipping from the collection center and receiptat transplant center were 7.5  108/kg (range:\1.0-
68.3) and 7.5 108/kg (range:\1.0-53.3). The cell con-
centration of all PBPC grafts at collection and shipping
was#5.0  108/mL.
Neutrophil and Platelet Recovery
Neither the interval from end of collection to re-
ceipt at transplant center nor interval from receipt at
transplant center to infusion was associated with he-
matopoietic recovery after PBPC transplants ( Tables
2B and 3B). Seven percent of patients developed sec-
ondary graft failure; a third of failures were associated
with recurrent leukemia.
Overall Mortality
Twohundred nine of 507 PBPC recipients are alive
with a 1-year probability of OS of 57% (95%CI 53%-
61%). Early mortality was not associated with the in-
terval from end to collection to receipt at transplant
center (OR 0.88, 95% CI 0.44-1.75, P 5 .711) or
from receipt at transplant center to infusion (OR
0.98, 95% CI 0.59-1.62, P 5 .932). Overall mortality
was not associated with transport time or from receipt
at transplant center to infusion (Table 4B). Overall
mortality was also not associated with time from end
of collection to infusion (the sum of transport time
and time from receipt at transplant center to infusion).
In subset analysis we examined survival after transplan-
tation of PBPC grafts from a single collection and did
not find an association between transport time or inter-
val from receipt at transplant center to infusion.DISCUSSION
This retrospective study using an observational
database is one of the first investigations on the impact
of long distance transport of a cellular component,
such as hematopoietic stem cells, on patient outcomes.
For a long time, platelet concentrates have been
obtained for thrombocytopenic recipients at special-
ized blood collection centers and effectively shipped
to remote distances by adhering to the Federal Regu-
latory codes for transportation of this product [15,
16]. Few studies and surveys have been published
that address collection, storage, processing, and
Table 3A. Probability of Platelet Recovery at 60 Days after
BM Transplants
Variables N
Odds Ratio for Recovery
(95% Confidence Interval) P-Value
Time from end of collection to receipt, hours
<20 883 1.00
$20 54 0.47 (0.26-0.83) .010
Time from receipt to infusion, hours
<6 703 1.00
$6 234 0.57 (0.41-0.80) .001
Performance score
90-100 705 1.00 <.001*
<90 139 0.42 (0.28-0.62) <.001
Unknown 93 0.72 (0.43-1.22) .221
Year of transplant
2003-2004 331 1.00
2000-2002 606 0.57 (0.40-0.79) <.001
*2-degree freedom test.
Table 4A. Risk factors for Overall Mortality after BM Trans-
plants
Variables N
Relative Risk
(95% Confidence
Interval) P-Value
Time from receipt to infusion, hours
<6 704 1.00
$6 234 1.18 (0.97-1.44) .107
Donor recipient HLA disparity and time from collection to
receipt, hours*
Well matched, <20 hours 494 1.00
Well matched, $20 hours 22 2.67 (1.64-4.35) <.001
Partially matched/mismatched,
<20 hours
390 1.00
Partially matched/
mismatched, $20 hours
32 0.88 (0.55-1.43) .611
Disease and disease status*
CML first chronic phase 223 1.00
AML frist clinical remission 153 2.06 (1.54-2.76) <.001
ALL first
clinical remission
125 1.58 (1.15-2.18) .005
MDS refractory anemia 33 1.75 (1.05-2.92) .033
CML second chronic phase 58 1.00
AML second clinical remission 162 0.72 (0.50-1.05) .091
ALL second clinical remission 184 0.81 (0.56-1.16) .245
Year of transplant
2003-2004 332 1.00
2000-2002 606 1.51 (1.23-1.84) <.001
CML indicates chronic myelogenous leukemia; AML, acute myelogenous
leukemia; ALL, acute lymphocyte leukemia; MDS, myelodysplastic syn-
dromes.
*First-order interaction.
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leagues [17] have shown that autologous hematopoi-
etic stem cells can be stored at 4C overnight prior
to CD34 cell selection, without affecting engraftment
or survival. Thus far, no investigators have addressed
transport of BM and PBPC grafts from volunteer un-
related donors and correlated with transplant out-
comes [18-24], although Lioznov and colleagues [25]
recently reported in a small series that unrelated donor
PBPC grafts transported and then frozen were associ-
ated with impaired function and engraftment after
thawing and infusion.
Our study involved nearly 200 stem cell collection
facilities and transplant centers scattered nationally
and internationally for almost 1500 unrelated donor
transplant procedures. Hematopoietic recovery after
PBPC transplants was not affected by transport times.
For BM grafts, a longer interval from end of collection
of product to infusion was associated with lower likeli-
hoods of platelet recovery but not neutrophil recovery,
after adjusting for other factors that influence platelet
recovery. A possible explanation in the observed differ-
ence between BM and PBPC transplants could be the
cell dose of the graft. The nucleated cell dose of PBPCTable 3B. Probability of Platelet Recovery at 60 Days after
PBPC Transplants
Variables N
Odds Ratio for Recovery
(95% Confidence Interval) P-Value
Time from end of collection to receipt, hours
<20 441 1.00
$20 65 0.68 (0.36-1.29) .235
Time from receipt to infusion, hours
<6 370 1.00
$6 136 0.59 (0.36-0.97) .036
Donor-recipient HLA disparity
Well matched 333 1.00
Partially matched
or mismatched
173 0.50 (0.31-0.79) .003grafts are approximately 1 log higher than that of BM,
and the additional cells may have minimized any
adverse impact of transport times on platelet viability.
It is possible that at ambient temperature, at which
most BM grafts were transported, cellular metabolism
is raised with accumulation of byproducts potentially
adversely affecting cell viability. Only 7% of BM grafts
(n 5 64) were refrigerated, but without monitoring of
temperature during transportation. Small numbers
and absence of documentation of temperature during
transport prevented us from examining for an effect
of temperature on transplant outcomes. Transport
temperatures were not monitored for PBPC grafts
either. However, minimal cell losses as measured byTable 4B. Risk Factors for Overall Mortality after PBPC
Transplants
Variables N
Relative Risk
(95% Confidence
Interval) P-Value
Time from end of collection to receipt, hours
<20 441 1.00
$20 65 0.95 (0.67-1.34) .751
Time from receipt to infusion, hours
<6 371 1.00
$6 135 0.92 (0.71-1.19) .532
Manipulation for ABO incompatibility
None 409 1.00
Yes 97 1.48 (1.12-1.95) .005
PBPC indicates peripheral blood progenitor cells.
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shipment for both graft types were documented.
Mortality rates after HLA-matched BM trans-
plants were higher when these grafts took longer than
20 hours to arrive at the transplant center after its
collection. Longer transport times, in general, were
noted predominantly when grafts were transported to
or from locations outside of the United States. The
observed higher mortality in the 22 patients with
good-risk leukemia and allele-matched donors, but
longer graft transport times in this analysis must be val-
idated in a larger cohort. Our inability to observe an as-
sociation between transport time and mortality after
HLA-mismatched BM transplants may be explained
by the fact that donor-recipient HLA disparity is
a key determinant for a successful outcome after unre-
lated donor transplantation.Mortality rates are high af-
ter HLA-mismatched transplants, and consequently,
any effect of longer transit time of the graft may be
obscured [5]. Nevertheless, time from collection to
receipt at transplant center and from receipt to infusion
should be minimized for BM grafts. Manipulation of
BM or PBPC grafts for ABO incompatibility was not
associated with hematopoietic recovery or mortality
rates. Transport times or the interval from receipt at
transplant center to infusion were not associated with
aGVHD or cGVHD (data not shown).
This analysis has several limitations: (1) data on
cell viability and sterility were not collected during
the study period, and (2) TNC doses reported were
obtained from the collection and transplant centers
and were subject to use of variable methods. Clearly,
future studies on the impact of transport time need
to collect more detailed data on cellular composition
and sterility at collection and receipt at the transplant
center. In such investigations, continuous temperature
monitoring may be an important maneuver; in our re-
port nearly all BM grafts were transported at ambient
temperature, whereas the vast majority of PBPC prod-
ucts were refrigerated during shipping. The ongoing
prospective, randomized Blood and Marrow Trans-
plant Clinical Trials Network (BMT CTN) trial
0201 comparing unrelated BM versus PBPC trans-
plants prescribes that both products be transported
at 2C to 8C. The United Network for Organ Shar-
ing (UNOS) policy requires that all organs and tissue
typing materials be transported at 2C to 8C.
Despite these limitations, this is the first attempt to
examine BM and PBPC transport time and its impact
on outcome after unrelated donor HCT. Prolonged
transport times were primarily, although not exclu-
sively, associated with international transport. It is
important to note that 30% of grafts with a prolonged
transport time also had a delay to infusion of longer
than 6 hours after receipt at the transplant center.
Delays encountered at transplant centers are not read-
ily explained by graft processing, as only a third of ma-nipulated grafts were infused $6 hours after their
receipt at the center. The findings of this analysis
suggest for BM grafts, delays in transport, and delays
at the transplant center are important and review of
current practices is encouraged. Although transport
times for BM grafts influence transplant outcomes,
selection of an unrelated donor should be dictated by
the most suitably matched donor regardless of geo-
graphic location of the donor/collection center, with
care taken to minimize delays during transport and at
the transplant center.ACKNOWLEDGMENTS
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